Therapeutic potential of non-peptide chymase inhibitors

Bibliography

• Doggrell SA, Wanstall JC. Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res 2004;61:653-62
   PubMed Web of Science ®Google Scholar
• Doggrell SA, Wanstall JC. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can J Physiol Pharmacol 2005;83:123-30
   PubMed Web of Science ®Google Scholar
• Omoto Y, Tokime K, Yamanaka K, et al. Human mast cell chymase cleaves pro-IL-18 and generates a novel biologically active IL-18 fragment. J Immunol 2006;177:8315-9
   PubMed Web of Science ®Google Scholar
• Tchougounova E, Lundequist A, Fajardo I, et al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix-2. J Biol Chem 2005;280:9291-6
   PubMed Web of Science ®Google Scholar
• Hamuro T, Kido H, Asada Y, et al. Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis. FEBS J 2007;274:3065-77
   PubMedGoogle Scholar
• Ihara M, Urata H, Shira K, et al. High cardiac angiotensin-II-forming activity in infracted and non-infarcted human myocardium. Cardiology 2000;94:247-53
   PubMed Web of Science ®Google Scholar
• Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-81
   PubMed Web of Science ®Google Scholar
• Batlle M, Roig E, Perez-Villa F, et al. Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human failure. J Heart Lung Transplant 2006;25:117-25
   Google Scholar
• Batlle M, Perez-Villa F, Lazaro A, et al. Correlation between mast cell density and myocardial fibrosis in congestive heart failure patients. Transplant Proc 2007;39:2347-9
   PubMedGoogle Scholar
• Takai S, Shiota N, Kobayashi S, et al. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett 1997;412:86-90
   PubMedGoogle Scholar
• Uehara Y, Urata H, Ideishi M, et al. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res 2002;55:870-6
   PubMed Web of Science ®Google Scholar
• Shiota N, Okunishi H, Fukamizu A, et al. Activation of two angiotensin-generating systems in the balloon injury artery. FEBS Lett 1993;323:239-42
   PubMedGoogle Scholar
• Nishimoto M, Takai S, Kim S, et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 2001;104:1274-9
   PubMed Web of Science ®Google Scholar
• Ohishi M, Ueda M, Rakugi H, et al. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J Hypertens 1999;17:547-53
   PubMedGoogle Scholar
• Ihara M, Urata H, Kinoshita A, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999;33:1399-405
   PubMed Web of Science ®Google Scholar
• Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44:1859-66
   PubMed Web of Science ®Google Scholar
• Ortlepp JR, Janssens U, Bleckmann F, et al. A chymase variant is associated with atherosclerosis in venous coronary artery bypass grafts. Coron Artery Dis 2001;12:493-7
   PubMed Web of Science ®Google Scholar
• Zanini A, Chetta A, Saetta M, et al. Chymase-positive mast cells play a role in the vascular component of airway remodeling in asthma. J Allergy Clin Immunol 2007;120:329-33
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu Y, Zhang Y, et al. Increased chymotrypsin-like protease (chymase) expression and activity in placentas from women with preeclampsia. Placenta 2007;28:263-9
   PubMed Web of Science ®Google Scholar
• Benoit C, Zavecz J, Wang Y. Vasoreactivity of chorionic plate arteries in response to vasocontrictors produced by preeclamptic placentas. Placenta 2007;28:498-504
   PubMedGoogle Scholar
• Muramatsum, Katada J, Hayashi I, Majima M. Chymase as a proangiogenic factor: a possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 2000;275:5542-62
   Google Scholar
• Kondo K, Muramatsu M, Okamoto Y, et al. Expression of chymase-positive cells in gastric cancer and its correlation with angiogenesis. J Surg Oncol 2006;93:36-42
   PubMedGoogle Scholar
• Badertscher K, Brönnimann M, Karlen S, et al. Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch Dermatol Res 2005;296:503-6
   PubMed Web of Science ®Google Scholar
• Groneberg DA, Bester C, Grützkau A, et al. Mast cells and vasculature in atopic dermatitis: potential stimulus of neoangiogenesis. Allergy 2005;60:90-7
   PubMed Web of Science ®Google Scholar
• Weidinger S, Rümmier L, Klopp N, et al. Association study of mast cell chymase polymorphisms with atony. Allergy 2005;60:1256-61
   PubMed Web of Science ®Google Scholar
• Yamada M, Ueda M, Naruko T. Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int 2001;59:1374-81
   PubMedGoogle Scholar
• Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14:1438-47
   Google Scholar
• Howard PS, Renfrow D, Schecter NM, Kucich U. Mast cell chymase is a possible mediator of neurogenic bladder fibrosis. Neurourol Urodyn 2004;23:374-82
   PubMedGoogle Scholar
• Andoh A, Deguchi Y, Inatomi O, et al. Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease. Oncol Rep 2006;16:103-7
   PubMed Web of Science ®Google Scholar
• Shimizu S, Satomura K, Aramaki T, et al. Hepatic chymase levels in chronic hepatitis: co-localization of chymase with fibrosis. Hepatol Res 2003;27:62-6
   PubMedGoogle Scholar
• Ikura Y, Ohsawa M, Shirai N, et al. Expression of angiotensin II type 1 receptor in human cirrhotic livers: its relation to fibrosis and portal hypertension. Hepatol Res 2005;32:107-16
   PubMedGoogle Scholar
• Komeda K, Jin D, Takai S, et al. Significance of chymase-dependent angiotensin II formation in the progression of human liver fibrosis. Hepatol Res 2007 [Epub ahead of print]
   PubMedGoogle Scholar
• Hirata K, Sugama Y, Ikura Y, et al. Enhanced mast cell chymase expression in human idiopathic interstitial pneumonia. Int J Mol Med 2007;19:565-70
   PubMedGoogle Scholar
• Orito K, Suzuki Y, Matsuda H, et al. Chymase is activated in the pulmonary inflammation and fibrosis induced by paraquat in hamsters. Tohoku J Exp Med 2004;203:287-94
   PubMed Web of Science ®Google Scholar
• Ebihara N, Funaki T, Takai S, et al. Tear chymase in vernal keratoconjunctivitis. Curr Eye Res 2004;28:417-20
   PubMed Web of Science ®Google Scholar
• Maruichi M, Oku H, Takai S, et al. Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: a possible involvement of chymase in the pathogenesis of macular hole patients. Curr Eye Res 2004;29:321-5
   PubMed Web of Science ®Google Scholar
• Suntory Ltd. Novel imidazolidinedione derivatives and use thereof as drugs. US5691335; 1997
   Google Scholar
• Suntory Ltd. Quinazoline derivatives and applications thereof. US5814631; 1998
   Google Scholar
• Daiichi Asubio Pharma Co. Ltd. Prevention or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient. US2002218338; 2002
   Google Scholar
• Daiichi Asubio Pharma Co. Ltd. Preventive or therapeutic drugs for various eosinophilia-related diseases containing chymase inhibitors as the active ingredient. US2002187989; 2002
   Google Scholar
• Daiichi Suntory Pharma Co. Ltd. Blood vessel lipid deposition-preventive agent comprising chymase inhibitor. US6921766; 2005
   Google Scholar
• Daiichi Asubio Pharma Co. Ltd. Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient. US2002183339; 2002
   Google Scholar
• Fukami H, Imajo S, Ito A, et al. Substituted 3-phenylsulfonylquinazoline-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase. Drug Des Discov 2000;17:69-84
   PubMedGoogle Scholar
• Daiichi Suntory Pharma Co. Ltd. Quinazole derivatives and pharmaceutical applications thereof. US2005148608; 2005
   Google Scholar
• Tanaka T, Muto T, Maruoka H, et al. Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5 diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett 2007;17:3431-4
   PubMed Web of Science ®Google Scholar
• Maruoka H, Muto T, Tanaka T, et al. Development of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as orally active human chymase inhibitors. Bioorg Med Chem Lett 2007;17:3435-9
   PubMed Web of Science ®Google Scholar
• Welfide Corp. Itchiness-relieving agents and itchiness-relieving effect potentiators. WO0051640; 2000
   Google Scholar
• Akahoshi F, Ashimori A, Sakashita H, et al. Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic alpha-keto heterocycles as novel inhibitors of human chymase. J Med Chem 2001;44:1286-96
   PubMedGoogle Scholar
• Akahoshi F, Ashimori A, Sakashita H, et al. Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic difluoromethylene ketones as novel inhibitors of human chymase. J Med Chem 2001;44:1297-304
   PubMedGoogle Scholar
• Aoyama Y, Uenaka M, Kii M, et al. Design, synthesis and pharmacological evaluation of 3-benzylazetidine-2-one based human chymase inhibitors. Bioorg Med Chem 2001;9:3065-75
   PubMedGoogle Scholar
• Takai S, Jin D, Sakaguchi M, et al. An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn J Pharmacol 2001;86:124-6
   PubMedGoogle Scholar
• Nippon Kayaku KK (JP). Acetamide derivatives and protease inhibitors. US6271238; 2001
   Google Scholar
• Nippon Kayaka Kk (US). Acetamide derivatives and use thereof. US6300337; 2001
   Google Scholar
• Takai S, Jin D, Nishimoto M, et al. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 2001;69:1725-32
   PubMed Web of Science ®Google Scholar
• Sod Conseils Rech (FR). Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure. WO2004010938; 2004
   Google Scholar
• Nippon Kayaku Kk (JP). Remedies or preventives for diseases in association with tissue fibrosis. WO03055488; 2003
   Google Scholar
• Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives. WO0222595; 2002
   Google Scholar
• Jin D, Takai S, Sakaguchi M, et al. An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J Pharmacol Exp Ther 2004;309:490-7
   PubMedGoogle Scholar
• Takai S, Jin D, Sakaguchi M, Miyazaki M. A single treatment with a specific chymase inhibitor, TY-51184, prevents vascular proliferation in canine grafted veins. J Pharmacol Sci 2004;94:443-8
   PubMedGoogle Scholar
• Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivative. WO03078419; 2003
   Google Scholar
• Masaki H, Mizuno Y, Tatui A, et al. Structure-activity relationship of benzo[b]thiophene-2-sulfonamide derivative as novel human chymase inhibitors. Biorg Med Chem Lett 2003;13:4085-88
   PubMedGoogle Scholar
• Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives. US2006116408; 2006
   Google Scholar
• Teijin Ltd. New triazinesulfone derivative. JP10245384; 1998
   Google Scholar
• Teijin Ltd. Benzimidazole derivative. JP2001192372; 2001
   Google Scholar
• Teijin Ltd. Benzimidazole derivative. JP2001199967; 2001
   Google Scholar
• Teijin Ltd. Benzimidazole derivative. JP2001199983; 2001
   Google Scholar
• Teijin Ltd. Aminobenzimidazole derivative. JP2001199968; 2001
   Google Scholar
• Teijin Ltd. Thiobenzimidazole derivative compounds, and usage as chymase activity inhibitors. WO0003997; 2000
   Google Scholar
• Teijin Ltd. Benzimidazole derivative, human chymase inhibitor, therapeutic agent and pharmaceutical composition based on thereof. WO0153291; 2001
   Google Scholar
• Teijin Ltd. Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients. WO03018061; 2003
   Google Scholar
• Hoshino F, Urata H, Inoue Y, et al. Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 2003;41(Suppl 1):S11-8
   PubMedGoogle Scholar
• Teijin Ltd. Drug containing chymase inhibitor as the active ingredient. US2007032466; 2007
   Google Scholar
• Santen Pharma Co. Ltd. Angiogenesis inhibitor comprising compound having chymase inhibitory effect as active ingredient. JP2001114699; 2001
   Google Scholar
• Santen Pharma Co. Ltd. Thiazine or pyrazine derivatives. US6713472; 2004
   Google Scholar
• Santen Pharma Co. Ltd. Novel thiazine derivatives. US2004097496; 2004
   Google Scholar
• Senju Pharma Co. Ltd. Lacrimation accelerating agent. JP2001058958; 2001
   Google Scholar
• Senju Pharma Co. Ltd. Tension-relieving agents for ciliary muscle. WO0130388; 2001
   Google Scholar
• Senju Pharma Co. Ltd. Novel imidazolidinedione derivatives and use thereof as drugs. WO02083649; 2002
   Google Scholar
• Janssen Pharmaceutica NV. Novel inhibitors of chymase. WO2005073214; 2005
   Google Scholar
• Mitsubishi Chem, Corp. Acylsulfonamide derivatives. WO0123349; 2001
   Google Scholar
• Dainippon Pharmaceutical Co. Ltd. Pyrrolidine derivatives and their use as chymase inhibitor. US2004102384; 2004
   Google Scholar
• Dainippon Pharmaceutical Co. Ltd. Thiazolimine compound and oxazolimine compound. US2007105908; 2007
   Google Scholar
• De Garavilla L, Greco MN, Sukumar N, et al. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem 2005;280:18001-7
   PubMed Web of Science ®Google Scholar
• Jin D, Takai S, Yamada M, et al. Beneficial effects of chymase inhibition during the acute phase of myocardial infarction. Life Sci 2002;71:437-46
   PubMedGoogle Scholar
• Jin D, Takai S, Sakaguchi M, et al. An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J Pharmacol Exp Ther 2003;309:490-7
   Google Scholar
• Takai S, Jin D, Sakaguchi M, et al. A novel chymase inhibitor, 4-[1-{[bis- (4-methyl-phenyl-methyl]-carbamoyl}-3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]benzoic acid (BCEAB), suppresses cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 2003;305:17-23
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003;107:2555-8
   PubMed Web of Science ®Google Scholar
• Soga Y, Takai S, Koyama T, et al. Attenuating effects of chymase inhibition on pericardial adhesion following cardiac surgery. J Card Surg 2007; 22:343-7
   PubMedGoogle Scholar
• Uehara Y, Urata H, Ideishi M, et al. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res 2002;55:870-6
   PubMed Web of Science ®Google Scholar
• Tsunemi K, Takai S, Nishimoto M, et al. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl-N-[{3,4-dioxo- 1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 2004;309:879-83
   PubMedGoogle Scholar
• Furubayashi K, Takai S, Jin D, et al. The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens Res 2007;30:349-57
   PubMedGoogle Scholar
• Takai S, Sakonjo H, Fukuda K, et al. A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther 2003;304:841-4
   PubMed Web of Science ®Google Scholar
• Kishi K, Muramatsu M, Jin D, et al. The effects of chymase on matrix metalloproteinase-2 activation in neointimal hyperplasia after balloon injury in dogs. Hypertens Res 2007;30:77-83
   PubMedGoogle Scholar
• Jin D, Ueda H, Taka S, et al. Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs. J Am Soc Nephrol 2005;16:1024-34
   PubMedGoogle Scholar
• Jin D, Ueda H, Taka S, et al. Roles of chymase in stenosis occurring after polytetrafluoroethylene graft implantations. Life Sci 2007;81:1291-300
   PubMedGoogle Scholar
• Muramatsu M, Yamada M, Takai S, Miyazaki M. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas. Br J Pharmacol 2002;137:554-60
   PubMedGoogle Scholar
• Sakaguchi M, Takai S, Jin D, et al. A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur J Pharmacol 2004;493:173-6
   PubMedGoogle Scholar
• Maruichi M, Takai S, Sugiyama T, et al. Role of chymase on growth of cultured canine Tenon's capsule fibroblasts and scarring in canine conjunctival flap model. Exp Eye Res 2004;79:111-8
   PubMedGoogle Scholar
• Konno T, Maruichi M, Takai S, et al. Effect of chymase on intraocular pressure in rabbits. Eur J Pharmacol 2005;524:132-7
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Takai S, Yamada M, Miyazaki M. Chymase inhibitors may prevent postoperative adhesion formation. Fertil Steril 2002;77:1044-8
   PubMedGoogle Scholar
• Okamoto Y, Takai S, Miyazaki M. Chymase inhibitor, BCEAB, suppressed peritoneal adhesion formation in hamster. J Surg Res 2002;107:219-22
   PubMedGoogle Scholar
• Okamoto Y, Takai S, Miyazaki M. Oral administration of a novel chymase inhibitor, NK3201, prevents peritoneal adhesion formation in hamsters. Jpn J Pharmacol 2002;90:94-6
   PubMedGoogle Scholar
• Kanemitsu H, Takai S, Tsuneyoshi H, et al. Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res 2006;29:57-64
   PubMedGoogle Scholar
• Kanemitsu H, Takai S, Tsuneyoshi H, et al. Chronic chymase inhibition preserved cardiac function after left ventricular repair in rats. Eur J Cardiothorac Surg 2008;33:25-31
   PubMedGoogle Scholar
• Palaniyandi SS, Nagai Y, Watanabe K, et al. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med (Maywood) 2007;232:1213-21
   Google Scholar
• Tomimori Y, Muto T, Fukami H, et al. Chymase participates in chronic dermatitis by inducing eosinophil infiltration. Lab Invest 2002;82:789-94
   PubMed Web of Science ®Google Scholar
• Watanabe N, Tomimori Y, Saito K, et al. Chymase inhibitor improves dermatitis in NC/Nga mice. Int Arch Allergy Immunol 2002;128:229-34
   PubMed Web of Science ®Google Scholar
• Shiota N, Kakizoe E, Shimoura K, et al. Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br J Pharmacol 2005;145:424-31
   PubMed Web of Science ®Google Scholar
• Watanabe N, Miura K, Fukuda Y. Chymase inhibitor ameliorates eosinophilia in mice infected with Nippostrongylus brasiliensis. Int Arch Allergy Immunol 2002;128:235-9
   PubMedGoogle Scholar
• Ishida K, Takai S, Murano M, et al. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther 2008;324:422-6
   PubMed Web of Science ®Google Scholar
• Tomimori Y, Muto T, Saito K, et al. Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol 2003;478:179-85
   PubMedGoogle Scholar
• Lindstedt KA, Mäyränpää MI, Kovanen PT. Mast cells in vulnerable atherosclerotic plaques: a view to kill. J Cell Mol Med 2007;4:739-58
   Google Scholar
• Reid AC, Silver RB, Levi R. Renin: at the heart of the mast cell. Immun Rev 2007;217:123-40
   PubMedGoogle Scholar